Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immix Biopharma, Inc.
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
May 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
May 04, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
May 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
April 04, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment
March 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
March 10, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
March 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
February 15, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
February 09, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
February 07, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
January 13, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
January 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
December 28, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 20, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
December 19, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
December 14, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 13, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
December 12, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.